In this episode, we review the ATA 2025 thyroid cancer guideline updates on tumors of uncertain malignant potential and when germline genetic testing is appropriate.

Topics include:

• NIFTP and related tumors with strict pathologic criteria and low malignant risk

• Management pearls and pitfalls of overtreatment

• Indications for germline testing (PTEN, DICER1, APC, Carney complex, Werner syndrome)

• Why non-syndromic familial thyroid cancer does not justify routine testing

• Screening approaches for relatives and risks of overdiagnosis

• Interpreting tumor sequencing results and confirming germline variants